FDA's Q-Submission Program for Medical Devices, SiMD / SaMD with Considerations for Using AI and ChatGPT
Watch the Course Now
Watch the Course Now
About the Course
FDA’s Q-Submission program has become increasingly important for companies developing medical devices, SaMD products, and software-enabled technologies that involve AI, ML, and LLM capabilities. The process provides manufacturers with formal pathways for obtaining FDA feedback before submission, helping organizations address technical, regulatory, and review concerns earlier in development. For novel and higher-risk products, particularly AI-enabled software applications, early interaction with FDA can reduce unnecessary review cycles and improve submission quality.
Recent FDA modernization efforts, including expanded use of generative AI and electronic submission tools such as eSTAR, are changing how submissions are prepared and reviewed. Organizations developing software-driven products must now address evolving expectations for software validation, maintenance, risk management, and predetermined change control planning. Clear understanding of Q-Sub mechanisms, submission pathways, and FDA expectations has become increasingly important for maintaining compliant and efficient product development programs.
Key Areas Covered
Quality training, expert insights, and answers that matter. Know your Expert
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.
Upcoming Courses
Your TalkFDA Webinar Experience
1. Confirmation
3. Access course materials
4. Watch The Streaming and Complete your Course


